Copyright
©The Author(s) 2018.
World J Clin Cases. Oct 26, 2018; 6(12): 493-500
Published online Oct 26, 2018. doi: 10.12998/wjcc.v6.i12.493
Published online Oct 26, 2018. doi: 10.12998/wjcc.v6.i12.493
Table 4 Composite of allogeneic bone marrow derived stem cell therapy trials
Author | Year of study | Fistula site | Study population | Method of administration | Healing type of fistula (unhealed, partially, fully) | Safety | Outcome |
Molendijk et al[1] | 2015 | Perianal | 21 | Patients assigned to four groups with curettage then intralesional fistula tract injection with stem cells or placebo (1) 1 × 107 (2) 3 × 107 (3) 9 ×107 (4) placebo | Week 24 fistula healing for groups (1) 66.7% (n = 5) (2) 85.7% (n = 5) (3) 28.6% (n = 5) (4) 33.3% (n = 6) | All patients reported pain and pus and/or discharge from fistula for 1 wk postoperatively One patient in each group (1, 2, 3, and placebo) developed perianal abscess | Use of intralesional injections of 3 × 107 was successful in fistula healing. |
- Citation: Turse EP, Dailey FE, Naseer M, Partyka EK, Tahan V. One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy. World J Clin Cases 2018; 6(12): 493-500
- URL: https://www.wjgnet.com/2307-8960/full/v6/i12/493.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i12.493